Oslo Footballplayers Iron Supplementation and Training (FIT) Study (Oslo-FIT)

August 25, 2020 updated by: Ågot Aakra

Iron Intake, Iron Status, Intestinal Health and Endurance Performance - Effects of Iron Supplementation in Young Female Football Players - a Pilot Study

The aim of the study is to characterize the diet and iron status of young female elite football players and examine the relationship between iron intake, iron status, hemoglobin levels, intestinal health and sports performance. In addition, the effects of low-dose iron supplements on iron stores will be investigated and whether such supplementation affects intestinal health, microbiota composition and biomarkers for oxidative stress.

Study Overview

Detailed Description

Iron deficiency can lead to fatigue and anemia. Because iron is necessary for the formation of new blood cells (hematopoiesis), it is an extensive practice internationally among athletes to take iron supplements in the belief that this will improve endurance performance and oxygen transport capacity by increasing red blood cell production. Although iron intake in menstruating women has shown to reduce the prevalence of anemia and iron deficiency as well as increasing hemoglobin values and iron stores. However iron supplementation increases the risk of iron excess and can result in undesirable effects such as constipation and abdominal pain as well as negative impact on intestinal epithelial permeability and increase in oxidative stress. Because iron is important for the replication and survival of almost all bacteria, with few exceptions, the intake of iron also affect the composition of the intestinal bacteria. Not surprisingly, both high and low iron levels affect the composition of the microbiota in the gut.

It is not known if young menstruating Norwegian female athletes cover their need for iron via the diet or whether extra intake in the form of a low-dose supplement could be beneficial in terms of hemoglobin levels and sports performance. Because iron preparations are not prescription and are sold in pharmacies, health food stores and larger grocery stores, this can lead to uncritical intake of iron. Since the use of iron preparations has been documented to be widespread in foreign sports environments, it is important to both characterize the iron status of Norwegian athletes and at the same time examine the beneficial value of iron supplements on sports performance as well as monitoring effects on microbiota composition and intestinal health.

The aim of the study is therefore to characterize the diet and iron status of young female elite football players and examine the relationship between iron intake, iron status, hemoglobin levels, intestinal health and sports performance. In addition, the effects of low-dose iron supplements will be investigated in relation to iron stores, hemoglobin levels and sports performance and whether such supplementation affects intestinal health, microbiota composition and biomarkers for oxidative stress.

Study Type

Interventional

Enrollment (Anticipated)

26

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ås, Norway, 1433
        • Norwegian University of Life Sciences

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (ADULT, OLDER_ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

- Female elite football players from two selected football clubs

Exclusion Criteria:

  • Pregnancy
  • Medical conditions that are worsened by taking iron supplements
  • Already taking iron supplements

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: BASIC_SCIENCE
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Iron supplements
The intervention group will ingest 27 mg iron supplement per day for three months while the control group will not ingest iron supplements.
The participants will be randomized to an intervention group or a control group. The intervention group will ingest 27mg iron daily for three months.
NO_INTERVENTION: Control group
The control group will not ingest iron supplements.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Diet composition
Time Frame: 3 months
Diet composition will be assessed using digital 7 day dietary records.
3 months
Iron intake
Time Frame: 3 months
Iron intake will be calculated based on average daily intake of iron according to the digital 7 day dietary recordings.
3 months
Serum Iron
Time Frame: 3 months
Iron status will be assessed by analyzing serum iron (µmol/L)
3 months
Serum transferrin
Time Frame: 3 months
Iron status will be assessed by analyzing serum transferrin (µmol/L)
3 months
Serum ferritin
Time Frame: 3 months
Iron status will be assessed by analyzing serum ferritin (µg/L)
3 months
Hemoglobin levels
Time Frame: 3 months
hemoglobin (Hb) (g/dl) will be analyzed in whole blood (EDTA) using an automated hematology analyzer.
3 months
LPS binding protein
Time Frame: 3 months
-Intestinal health will be measured using biomarkers of intestinal leakage in serum and feces such as sLPS binding protein (LBP) (ug/ml)
3 months
Neutrophil gelatinase-associated lipocalin
Time Frame: 3 months
-Intestinal health will be measured using biomarkers of intestinal leakage in serum and feces such as fecal neutrophil gelatinase-associated lipocalin (NGAL) (ng/g feces)
3 months
Serum cytokines
Time Frame: 3 months
-Intestinal health will be measured using serum biomarkers of systemic inflammation (e.g. serum cytokines such as IL-1, IL-6, and TNF-α pg/ml).
3 months
Sports performance
Time Frame: 3 months
Sports performance specific for football will be be measured using the Yo-Yo Intermittent Recovery Test (YYIR1).
3 months
Differential counts
Time Frame: 3 months
Differential counts (% of WBC) will be analyzed in whole blood (EDTA) using an automated hematology analyzer.
3 months
Ferric reducing ability of plasma
Time Frame: 3 months
-Oxidative stress will be assessed measuring the ferric reducing ability of plasma (FRAP)
3 months
Diacron reactive oxygen metabolites
Time Frame: 3 months
-Oxidative stress will be assessed measuring biomarkers of total oksidativ stress e.g. diacron reactive oxygen metabolites (dROM).
3 months
Microbiota composition
Time Frame: 3 months
-Microbiota composition will be analyzed mainly using 16S rRNA gene sequencing. The main effect of the intervention on the microbiota will be tested based on crude alpha and beta diversity indices but we will also apply advanced multivariate methods.
3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

August 11, 2020

Primary Completion (ANTICIPATED)

November 20, 2020

Study Completion (ANTICIPATED)

November 20, 2020

Study Registration Dates

First Submitted

August 13, 2020

First Submitted That Met QC Criteria

August 24, 2020

First Posted (ACTUAL)

August 26, 2020

Study Record Updates

Last Update Posted (ACTUAL)

August 27, 2020

Last Update Submitted That Met QC Criteria

August 25, 2020

Last Verified

August 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 969159570_KBM_SKB2020

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

IPD Plan Description

An IPD sharing plan is not ready for the project

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Athletes

Clinical Trials on Iron supplement (27mg)

3
Subscribe